37,549 Shares in Repligen Corporation $RGEN Purchased by Moore Capital Management LP

Moore Capital Management LP purchased a new stake in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, Holdings Channel reports. The firm purchased 37,549 shares of the biotechnology company’s stock, valued at approximately $5,123,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its holdings in shares of Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC bought a new stake in shares of Repligen in the 2nd quarter worth approximately $380,756,000. Opti Capital Management LP acquired a new stake in shares of Repligen during the 4th quarter valued at $2,399,209,000. Wasatch Advisors LP lifted its holdings in shares of Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after purchasing an additional 346,720 shares during the last quarter. Finally, Maverick Capital Ltd. acquired a new position in shares of Repligen in the first quarter worth about $178,946,000. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.60% of the stock is currently owned by corporate insiders.

Repligen Price Performance

Shares of Repligen stock opened at $180.98 on Tuesday. The firm has a market cap of $10.21 billion, a P/E ratio of 247.92, a price-to-earnings-growth ratio of 3.22 and a beta of 1.03. The firm’s 50-day simple moving average is $153.08 and its 200-day simple moving average is $133.28. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, research analysts expect that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on RGEN shares. Jefferies Financial Group reaffirmed a “hold” rating and set a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. HSBC cut their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Finally, Evercore reissued an “outperform” rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Buy” and an average price target of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.